Chenglong Zhao1, Zhitao Han2, Hui Xiao1, Cheng Yang1, Yongfei Zhao3, Tianqi Fan1, Zhengwang Sun1, Tielong Liu4, Jianru Xiao5. 1. Spine Tumor Center, Changzheng Hospital, Second Military Medical University, Fengyang Rd 415#, Huangpu District, Shanghai, China. 2. Guangxi University of Chinese Medicine, Mingxiu Rd 179#, Mingxiu District, Nanning, Guangxi Provinve, China. 3. Department of Orthopedics, The General Hospital of Chinese People's Liberation Army, Fuxing Road 28#, Beijing, China. 4. Spine Tumor Center, Changzheng Hospital, Second Military Medical University, Fengyang Rd 415#, Huangpu District, Shanghai, China. czyyltl@163.com. 5. Spine Tumor Center, Changzheng Hospital, Second Military Medical University, Fengyang Rd 415#, Huangpu District, Shanghai, China. jianruxiao83@163.com.
Abstract
PURPOSE: Liposarcoma, one of the most common soft tissue sarcomas originates from primitive mesenchymal cells. But spinal involvement of either primary or metastatic liposarcoma is rare. Here we present our experience of seven consecutive patients with spinal liposarcoma. METHOD: We retrospectively reviewed our patients who have spinal liposarcoma from January 2009 to December 2013. All patients were surgically treated at least once at our spine tumor center and be confirmed as liposarcoma after surgery. All patients' information and follow-up data were collected afterwards. RESULTS: A total of six male and one female patients have been included. Five of them had mobile spinal involvement while the others had sacral involvement. Six piecemeal and one en-bloc resections were successfully performed. Patients' Frankel scores were upgraded with one level or at least preserved postoperatively. The average time of follow-up was 24.6 ± 13.9 months. Three patients died 13, 15 and 24 months after surgical treatment, respectively while the other four patients were still alive and one of them alive with disease at the end of follow-up. CONCLUSION: The outcome and prognosis of spinal liposarcoma is poor, and surgical resections should be considered when diagnosis is confirmed. For those whose tumors were too large to resect and/or with multiple metastases, effective treatment options are currently limited. Therefore, multidisciplinary treatment should be adopted, intraoperative chemotherapy, systemic chemotherapy and radiotherapy for instance.
PURPOSE:Liposarcoma, one of the most common soft tissue sarcomas originates from primitive mesenchymal cells. But spinal involvement of either primary or metastatic liposarcoma is rare. Here we present our experience of seven consecutive patients with spinal liposarcoma. METHOD: We retrospectively reviewed our patients who have spinal liposarcoma from January 2009 to December 2013. All patients were surgically treated at least once at our spine tumor center and be confirmed as liposarcoma after surgery. All patients' information and follow-up data were collected afterwards. RESULTS: A total of six male and one female patients have been included. Five of them had mobile spinal involvement while the others had sacral involvement. Six piecemeal and one en-bloc resections were successfully performed. Patients' Frankel scores were upgraded with one level or at least preserved postoperatively. The average time of follow-up was 24.6 ± 13.9 months. Three patients died 13, 15 and 24 months after surgical treatment, respectively while the other four patients were still alive and one of them alive with disease at the end of follow-up. CONCLUSION: The outcome and prognosis of spinal liposarcoma is poor, and surgical resections should be considered when diagnosis is confirmed. For those whose tumors were too large to resect and/or with multiple metastases, effective treatment options are currently limited. Therefore, multidisciplinary treatment should be adopted, intraoperative chemotherapy, systemic chemotherapy and radiotherapy for instance.
Authors: Louis-Charles Moreau; Robert Turcotte; Peter Ferguson; Jay Wunder; Paul Clarkson; Bas Masri; Marc Isler; Norbert Dion; Joel Werier; Michelle Ghert; Benjamin Deheshi Journal: Ann Surg Oncol Date: 2011-11-04 Impact factor: 5.344
Authors: Matthew T Ballo; Gunar K Zagars; Raphael E Pollock; Robert S Benjamin; Barry W Feig; Janice N Cormier; Kelly K Hunt; Shreyaskumar R Patel; Jonathan C Trent; Sam Beddar; Peter W T Pisters Journal: Int J Radiat Oncol Biol Phys Date: 2006-11-02 Impact factor: 7.038
Authors: Marco Fiore; Federica Grosso; Salvatore Lo Vullo; Elisabetta Pennacchioli; Silvia Stacchiotti; Andrea Ferrari; Paola Collini; Laura Lozza; Luigi Mariani; Paolo G Casali; Alessandro Gronchi Journal: Cancer Date: 2007-06-15 Impact factor: 6.860
Authors: Nicolas Macagno; Stéphane Fuentes; Gonzague de Pinieux; André Maues de Paula; Sébastien Salas; Jean-Camille Mattéi; Charlotte Dupuis; Romain Appay; Alain Aurias; Henry Dufour; Dominique Figarella-Branger; Corinne Bouvier Journal: Case Rep Pathol Date: 2017-03-09